Golden
Lundbeckfond Ventures

Lundbeckfond Ventures

An evergreen life science venture capital firm in Copenhagen that invests in early and late stage ventures

Lundbeckfonden Ventures is an evergreen life science venture capital firm in Copenhagen that invests in early and late stage ventures. Established in the autumn of 2009 and wholly owned by Lundbeck Foundation, it offers flexible and long-term investments. It typically invests in Series B, Series A, Series C, and in post-IPO equity. Its portfolio companies include Spero Therapeutics, SANIFIT, Reneo Pharmaceuticals, Aura Biosciences, River Vision Development, Vtesse, Ziarco, Celladon and Asante Solutions.

Since 2009, the company has invested in 31 life science companies in the US and Europe, and have an active portfolio of about 20 companies representing a wide range of therapeutic areas. It invests around DKK 350 to 400 million annually.

Timeline

2009

Founded

Funded Companies

Company
Description
Website
Industry
Location

A pharmaceutical company developing tissue factor therapies for the treatment of cancer and diseases.

A company developing drugs for orphan and rare diseases

A biopharmaceutical company developing drugs for the treatment of chronic inflammatory diseases

A biopharmaceutical company developing therapeutics for skin disorders

A company that develops cell therapies to treat kidney diseases

scPharmaceuticals is a Burlington, Massachusetts-based company.

DySISmedical is a Edinburgh-based company.

12 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Birgitte Schou

Vice President Finance

Casper Breum

Partner

Jette Bundgard

Associate

Johan Kördel

Senior Partner

Mette Kirstine Agger

Managing Partner

Further reading

Title
Author
Link
Type
Date
+ Add new row

Documentaries, videos and podcasts

Title
Date
Link
+ Add new row

Companies

Company
CEO
Location
Products/Services

Imara

DYSIS Medical

ENTEROME Bioscience

Iconic Therapeutics

Reneo Pharmaceuticals

SANIFIT

SNIPR Biome

Tiburio Therapeutics

Trevi Therapeutics

References